{"id":3839,"date":"2020-12-26T05:39:37","date_gmt":"2020-12-26T05:39:37","guid":{"rendered":"https:\/\/thenewzbiz.com\/?p=3839"},"modified":"2020-12-26T05:39:37","modified_gmt":"2020-12-26T05:39:37","slug":"glenmark-pharmaceuticals-and-menarini-enter-into-exclusive-licensing-agreement-for-commercializing-ryaltris-nasal-spray-across-numerous-markets-throughout-europe","status":"publish","type":"post","link":"https:\/\/thenewzbiz.com\/?p=3839","title":{"rendered":"Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe"},"content":{"rendered":"

The Newz Biz Team, PUNE<\/strong><\/p>\n

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.<\/p>\n

Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.<\/p>\n

Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris™ in these markets. Menarini will be responsible for the scientific information and the commercialization of Ryaltris™ in those markets, following regulatory approval. Glenmark will receive an upfront payment as well as launch & sales based milestone payments from Menarini for Ryaltris™ sales.<\/p>\n

\u201cWe are excited to partner with Menarini for Ryaltris™ across Europe as they have a proven track record in partnering and commercialising respiratory products in the region. This partnership is another step in establishing Glenmark\u2019s respiratory focus in Europe. While Glenmark will launch Ryaltris™ through its own front ends in some markets, this arrangement will allow the product to compete across Europe. This is also aligned with our vision to make Ryaltris™ the first global brand of Glenmark by launching it in several markets across the world,\u201d said Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) Glenmark Pharmaceuticals.<\/p>\n

\u201cWe are delighted to have undertaken this exclusive licensing agreement with\u00a0Glenmark Pharmaceuticals. Ryaltris™ is a perfect addition to our European respiratory and allergy portfolio and we\u00a0can count on our established experience in the relevant\u00a0therapeutic area\u00a0to bring\u00a0this novel option\u00a0to patients.\u00a0 We look forward to receiving\u00a0Ryaltris™ registration and being able to launch operations as soon as practicable,\u201d commented Pio Mei, General Manager Menarini Group<\/p>\n

Ryaltris™ (olopatadine hydrochloride and mometasone furoate) Nasal Spray, the company\u2019s respiratory pipeline asset is partnered with Hikma Pharmaceuticals PLC for the commercialisation in the US market.\u00a0 Ryaltris™ sales continues to progress well in Australia, after the successful launch earlier this year by Glenmark\u2019s partner, Seqirus Pty. Ltd. Ryaltris\u00ae ™ was also recently launched in South Africa. Glenmark plans to initiate commercial launch in Ukraine and Uzbekistan in the next few months. Glenmark is supporting its partner Yuhan Corporation to launch Ryaltris™ by the end of the March 2021 in South Korea.<\/p>\n

Glenmark has received approval for Ryaltris™ in Australia, South Korea, Cambodia, Ukraine, Uzbekistan, Namibia and South Africa. The company had already filed an application for Ryaltris™ approval in the European Union, Canada, Russia, Brazil, Malaysia, Saudi Arabia and several other markets. Glenmark\u2019s partner in China, Grand Pharmaceutical (China) Co. Ltd., plans to submit an IND in this financial year.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Newz Biz Team, PUNE Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region. Ryaltris™ [olopatadine hydrochloride (665 […]<\/p>\n","protected":false},"author":2,"featured_media":3837,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,505],"tags":[822],"class_list":["post-3839","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news","category-press-releases","tag-glenmark-pharmaceuticals-and-menarini-enter-into-exclusive-licensing-agreement-for-commercializing-ryaltris-nasal-spray-across-numerous-markets-throughout-europe"],"_links":{"self":[{"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/posts\/3839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3839"}],"version-history":[{"count":1,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/posts\/3839\/revisions"}],"predecessor-version":[{"id":3840,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/posts\/3839\/revisions\/3840"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=\/wp\/v2\/media\/3837"}],"wp:attachment":[{"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3839"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3839"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thenewzbiz.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}